首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Novel structural insights for drug design of selective 5-HT(2C) inverse agonists from a ligand-biased receptor model.
【24h】

Novel structural insights for drug design of selective 5-HT(2C) inverse agonists from a ligand-biased receptor model.

机译:来自配体偏置受体模型的选择性5-HT(2C)逆激动剂的药物设计的新结构见解。

获取原文
获取原文并翻译 | 示例
           

摘要

Structure-based design of compounds targeting monoamine receptors, within the class-A G-protein coupled receptors, has been enriched by the recent crystallization of the beta1 and beta2 adrenoceptors. On the basis of ligand-biased homology modeling and docking-scoring calculations, a ritanserin-biased 5-HT(2C) receptor model has been built and used in a highly efficient virtual screening protocol to discriminate specifically 5-HT(2C) inverse agonists in a fuzzy dataset including hundreds of compounds with known experimental values of 5-HT(2C) affinity and activity. The resulting fingerprint of interaction displays hotspots in the third transmembrane alpha-helix and the second extracellular loop selectively bound by most 5-HT(2C) inverse agonists.
机译:基于结构的靶向单胺受体的化合物的设计已经在β1和β2肾上腺素受体的最近结晶中富集。 在配体偏置的同源性建模和对接评分计算的基础上,已经建立并用于高效的虚拟筛选方案中的蓖麻酶偏置的5-HT(2C)受体模型,以确定特异性为5-HT(2C)逆激动剂 在模糊数据集中,包括数百种化合物,具有已知的5-HT(2C)亲和力和活性的实验值。 所得到的相互作用指纹显示第三跨膜α-螺旋中的热点,并选择性地由大多数5-HT(2C)逆激动剂选择性地结合的第二细胞外环。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号